On the nature of Mycobacterium tuberculosis-latent bacilli

European Respiratory Journal

Volumn 24, Issue 6, 2004, Pages 1044-1051

  Cardona, P J ^a   Ruiz Manzano, J ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Animal model; Mycobacterium tuberculosis; Pathogenesis; Tuberculosis

Indexed keywords

RIFAMPICIN;

ARTICLE; BACTERIAL METABOLISM; CELL METABOLISM; DORMANCY; FIBROSIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; REINFECTION; STRESS; TUBERCULOSIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VIRULENCE FACTORS;

EID: 10444253957     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00072604     Document Type: Article

References (69)

1. World Health Organization. Global tuberculosis control. WHO Report 2001 (WHO/CDS/TB/2001.287). Geneva, World Health Organization, 2001.
2. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279.
3. Rieder HL. Interventions for tuberculosis control and elimination. Paris, International Union Against Tuberculosis and Lung Diseases, 2002.
4. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970; 17: 28-106.
5. Balasubramanian V, Wiegeshaus EH, Taylor BT, Smith DW. Pathogenesis of tuberculosis: pathway to apical localization. Tuber Lung Dis 1994; 75: 168-178.
6. Milic-Emili J. Topographical inequality of ventilation. In Crystal RG, West JB, eds. The lung: scientific foundations. Vol. 1. New York, Raven Press Ltd, 1991; pp. 1043-1051.
7. Medlar EM. The pathogenesis of minimal pulmonary tuberculosis: a study of 1225 necropsies in cases of sudden and unexpected death. Am Rev Tuberc 1948; 58: 583-611.
8. Ho RS, Fok JS, Harding GE, Smith DW. Host-parasite relationships in experimental airborne tuberculosis. VII. Fate of Mycobacterium tuberculosis in primary lung lesions and in primary lesion-free lung tissue infected as a result of bacillemia. J Infect Dis 1978; 138: 237-241.
9. Sweany HC, Cook CE, Kegerreis R. A study of the position of primary cavities in pulmonary tuberculosis. Am Rev Tuberc 1931; 24: 558-582.
10. Lucas SB. Histopathology. In: Davies PDO, ed. Clinical tuberculosis. London, Chapman & Hall, 1998; pp. 113-127.
11. Mitchison DA, Dickinson JM. Bactericidal mechanisms in short-course chemotherapy. Bull Int Union Tuberc 1978; 53: 254-259.
12. Corper HJ, Cohn ML. The viability and virulence of old cultures of tubercle bacilli: studies on twelve-year broth cultures maintained at incubator temperature. Am Rev Tuberc 1933; 28: 856-874.
13. Wayne LG. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. Am Rev Respir Dis 1976; 114: 807-811.
14. Wayne L, Lin K-Y. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982; 37: 1042-1049.
15. Mochizuki M. Kinetics of oxygen and carbon dioxide reactions. In: The lung: scientific foundations. Crystal RG, West JB, et al., eds. New York, Raven Press Ltd, 1991; pp. 1241-1252.
16. Morita RY. Bioavailability of energy and the starvation state. In: Kjelleberg S, ed. Starvation in bacteria. New York, Plenum Press, 1993; pp. 1-24.
17. Michele TM, Ko C, Bishai WR. Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors. Antimicrob Agents Chemother 1999; 43: 218-225.
18. DeMaio J, Zhang Y, Ko C, Bishai WR. Mycobacterium tuberculosis sigF is part of a gene cluster with similarities to the Bacillus subtilis sigF and sigB operons. Tuber Lung Dis 1997; 78: 3-12.
19. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998; 6: 107-112.
20. Kaprelyants AS, Gottschal JC, Kell DB. Dormancy in nonsporulating bacteria. FEMS Microbiol Rev 1993; 10: 271-285.
21. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054-2058.
22. Shleeva MO, Bagramyan K, Telkov MV, et al. Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology 2002; 148: 1581-1591.
23. Mukamolova GV, Kaprelyants AS, Young DI, Young M, Kell DB. A bacterial cytokine. Proc Natl Acad Sci U S A 1998; 95: 8916-8921.
24. Zhang Y, Yang Y, Woods A, Cotter RJ, Sun Z. Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem Biophys Res Commun 2001; 284: 542-547.
25. McCune RM, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956; 104: 737-760.
26. Wallace JG. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Rev Respir Dis 1961; 83: 866-871.
27. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004; 84: 29-44.
28. Stewart GR, Robertson BD, Young DB. Tuberculosis: a problem with persistence. Nature Rev 2003; 1: 97-105.
29. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-738.
30. Grange JM. Immunophysiology and immunopathology of tuberculosis. In: Davies PDO, ed. Clinical tuberculosis. London, Chapman & Hall, 1998; pp. 129-152.
31. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997; 119: 183-201.
32. Grzybowski S, Allen EA. The challenge of tuberculosis in decline: a study based on the epidemiology of tuberculosis in Ontario, Canada. Am Rev Respir Dis 1964; 90: 707-720.
33. Stead WW, Lofgren JP. Does the risk of tuberculosis increase with old age? J Infect Dis 1983; 147: 951-955.
34. Canetti G. Endogenous reactivation and exogenous reinfection. Their relative importance with regard to the development of non-primary tuberculosis. Bull Int Union Tuberc 1972; 47: 116-122.
35. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
36. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76: 771S-775S.
37. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1980; 1: 231-241.
38. Ulrich T, Kaufmann SHE. Cell-mediated immune response. In Rom WN, Garay SM, eds. Tuberculosis. Philadelphia, Lippincott Williams & Wilkins, 2004; pp. 251-262.
39. Meylan PRA, Richman DD, Konbluth RS. Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure. Am Rev Respir Dis 1992; 145: 947-953.
40. Much H. Uber die granulare, nach Zaiehl nicht darsellbare form des tuberkuloservirus. Beitrage Klinisches Tuberkulose 1907; 8: 85.
41. de Wit D, Mitchison DA. DNA analysis demonstrates that mycococcus forms are not mycobacteria. Tuber Lung Dis 1993; 74: 96-99.
42. Khomenko AG. The variability of Mycobacterium tuberculosis in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Tubercle 1987; 68: 243-253.
43. Mattman LH. Cell wall deficient forms: stealth pathogens. Boca Raton, CRC Press, 2000.
44. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966; 123: 445-468.
45. Cardona PJ, Llatjós R, Gordillo S, et al. Towards a "human-like" model of tuberculosis: local inoculation of LPS in lungs of Mycobacterium tuberculosis aerogenically infected mice induces intragranulomatous necrosis. Scand J Immunol 2001; 53: 65-71.
46. Cardona PJ, Llatjós R, Gordillo S, et al. Evolution of granulomas in mice infected aerogenically with Mycobacterium tuberculosis. Scand J Immunol 2000; 52: 156-163.
47. Green GM. Alveolobronchiolar transport mechanisms. Arch Intern Med 1973; 131: 109-114.
48. Cardona PJ, Gordillo S, Díaz J, et al. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect Immun 2003; 71: 5845-5854.
49. Andersen P, Askgaard D, Ljungqvist L, Bennedsen J, Heron I. Proteins released from Mycobacterium tuberculosis during growth. Infect Immun 1991; 59: 1905-1910.
50. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis 1993; 167: 1481-1497.
51. Stumbles PA, McWilliam AS, Holt PG. Dendritic cells and mucosal macrophages. In: Mucosal immunology. Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, eds. San Diego, Academic Press, 1999; pp. 397-412.
52. Dunn PL, North RJ. Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice. Infect Immun 1995; 63: 3428-3437.
53. Cardona PJ, Gordillo S, Amat I, et al. Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. Tuberculosis (Edinb) 2003; 83: 351-359.
54. Rees RJW, Hart PD. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br J Exp Pathol 1961; 42: 83-88.
55. Cardona PJ, Julian E, Valles X, et al. Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis. Scand J Immunol 2002; 55: 639-645.
56. Hernandez-Pando R, Jeyanathan M, Mengistu G, et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000; 356: 2133-2138.
57. Thakker B, Black M, Foulis AK. Mycobacterial nucleic acids in sarcoid lesions. Lancet 1992; 339: 1537.
58. Vokurka M, Lecossier D, du Bois RM, et al. Absence of DNA from mycobacteria of the M. tuberculosis complex in sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1000-1003.
59. Walker DA, Taylor IK, Mitchell DM, Shaw RJ. Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65kDa antigen gene, in the diagnosis of tuberculosis. Thorax 1992; 47: 690-694.
60. Harmon KR, Marinelli WA, Henke CA, Bitterman PB. Regulation of cell replication. In: Crystal RG, West JB, eds. The lung: scientific foundations. New York, Raven Press Ltd, 1991; pp. 105-129.
61. Katzenstein AA, Askin FB. Surgical pathology of nonneoplastic lung disease. Philadelphia, WB Saunders, 1990.
62. Canetti G. Exogenous reinfection: its relative impact with regard to development of pulmonary tuberculosis. A study of the pathology. Tubercle 1950; 31: 224-233.
63. Opie EL, Aronson JD. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol 1927; 4: 121.
64. Orme M. The latent tuberculosis bacillus (I'll let you know if I ever meet one). Int J Tuberc Lung Dis 2001; 5: 589-593.
65. Beck JS. Skin changes in the tuberculin test. Tubercle 1991; 72: 81-87.
66. Horwitz O. The risk of tuberculosis in different groups of the general population. Scand J Respir Dis 1970; 72: 55-60.
67. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
68. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
69. Nardell E, McInnis B, Thomas B, Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986; 315: 1570-1575.